Cypralis

[Cypralis @cypralispharma]

Our paper in collaboration with @SelciaLtd and @GileadSciences entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ has been selected as a featured article for @JMedChem https://t.co/Iag51g5CSc #DrugDiscovery

[Sciad Communications @sciadcomms]

.@Medherant wins ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards! https://t.co/fZxeGXNr2b #biotech #medtech #awards #TEPIPatch

[Sciad Communications @sciadcomms]

.@BiotechandMoney announces keynote speaker update for World HealthEx Forum https://t.co/GFVDzEPOh7 #biotech #investment #health

[Cypralis @cypralispharma]

.@cypralispharma receive funding of $524,000 from @TheADDF https://t.co/Ahoaj5Kn69’s-drug-discovery-foundation #pharma #biotech #alzheimers

[Genetic Engineering & Biotechnology News @GENbio]

. @cypralispharma Wins @TheADDF Funding to Support Cyclophilin D Inhibitor Program: https://t.co/1wYps9xvtI

[Cypralis @cypralispharma]

.@cypralispharma granted new Innovate UK early stage award - https://t.co/7IXfDxaqVC #biotech #pharma

[Cypralis @cypralispharma]

Cypralis has acquired a significant portfolio of cyclophilin inhibitor assets from #SCYNEXIS, find out more here: https://t.co/alFWXTVFzr

[Cypralis @cypralispharma]

Cypralis is pleased to announce the appointment of Dr Michael Peel as our new CSO: https://t.co/v64BgL4L3w

[Cypralis @cypralispharma]

Cypralis is collaborating with Johnson & Johnson Innovation in the field of #Neurodegenerative diseases https://t.co/weMehpzzbE

[Cypralis @cypralispharma]

Cypralis has been awarded funding by @Innovate_uk to generate selective Cyclophilin D inhibitors: https://t.co/uGy5CEmJUZ

[Cypralis @cypralispharma]

New PPIase drug pipeline from @Cypralispharma aims to discover and develop novel medicines for acute & chronic degenerative diseases